Gilead Sciences Gears Up for Clinical Trials of Inhaled Remdesivir

Gilead Sciences has gotten approval from the FDA to launch a phase 1 trial of an inhaled version of its antiviral remdesivir for the earlier treatment of COVID-19 patients.

The drugmaker said it plans to start trials in August.